The Performance of Immunocytochemistry Staining as Triaging Tests for High-Risk HPV-Positive Women: A 24-Month Prospective Study.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
02
2020
revised:
27
04
2020
accepted:
12
05
2020
entrez:
23
6
2020
pubmed:
23
6
2020
medline:
23
6
2020
Statut:
epublish
Résumé
It is urgent to develop an accurate approach to improve the predictive performance of hrHPV-based screening. The aim is to evaluate the performance of p16/Ki-67 and p16/MCM2 staining to triage high-risk human papillomavirus- (hrHPV-) positive women. Cervical specimens were collected from eligible women and tested for hrHPV genotyping, cytology, p16/Ki-67, and p16/MCM2 staining at baseline. Women were invited to participate in follow-up screening by cytology and hrHPV testing at 24 months. Positive women received colposcopy and biopsies. Histopathological diagnoses were the gold standard. 485 women came back for the follow-up screening. The positive rate of p16/Ki-67 was 20.2% and of p16/MCM2 was 27.2%. The positive rates of p16/Ki-67 (
Identifiants
pubmed: 32565806
doi: 10.1155/2020/6878761
pmc: PMC7271243
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6878761Informations de copyright
Copyright © 2020 Yu-Cong Li et al.
Déclaration de conflit d'intérêts
The authors declare no potential conflicts of interest.
Références
Histol Histopathol. 2007 Jun;22(6):587-92
pubmed: 17357088
Hum Pathol. 2005 Oct;36(10):1101-7
pubmed: 16226110
J Med Virol. 2019 Jul;91(7):1342-1350
pubmed: 30854653
Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):628-37
pubmed: 21297040
Cancer. 2007 Feb 25;111(1):58-66
pubmed: 17186505
Lancet Oncol. 2013 Feb;14(2):168-76
pubmed: 23261355
Lancet Oncol. 2008 Oct;9(10):929-36
pubmed: 18805733
Oncotarget. 2017 Aug 3;8(48):83890-83899
pubmed: 29137390
Gynecol Oncol. 2011 Jun 1;121(3):505-9
pubmed: 21420158
Int J Cancer. 2014 Apr 1;134(7):1715-24
pubmed: 24105727
Cancer Cytopathol. 2013 Sep;121(9):473-82
pubmed: 23907807
Lancet Oncol. 2011 Jul;12(7):663-72
pubmed: 21684207
Cancer Epidemiol. 2019 Apr;59:123-128
pubmed: 30739069
J Natl Cancer Inst. 2013 Oct 16;105(20):1550-7
pubmed: 24096620
Int J Cancer. 2010 Aug 1;127(3):646-56
pubmed: 19960441
Int J Cancer. 2017 Aug 1;141(3):437-446
pubmed: 28297074
Int J Cancer. 2011 Jun 15;128(12):2898-910
pubmed: 20734388
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2536-45
pubmed: 18842994
Nat Rev Cancer. 2005 Feb;5(2):135-41
pubmed: 15660109
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
Vaccine. 2012 Nov 20;30 Suppl 5:F88-99
pubmed: 23199969
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
JAMA Oncol. 2019 Feb 1;5(2):181-186
pubmed: 30325982
Cancer Cytopathol. 2011 Jun 25;119(3):158-66
pubmed: 21442767
Int J Cancer. 2018 Aug 15;143(4):851-860
pubmed: 29569718
Clin Cancer Res. 2012 Aug 1;18(15):4154-62
pubmed: 22675168